White brings more than 20 years of experience in the medical device, biotech, and healthcare fields to drive commercialization of the SoftVue™ 3D Whole Breast Ultrasound Tomography System
Delphinus Medical Technologies, a pioneering medical imaging company that developed the SoftVue™ 3D Whole Breast Ultrasound Tomography System (SoftVue), today announced the appointment of Scott A. White to the position of chief commercial officer (CCO). White will lead Delphinus’ commercialization efforts for the SoftVue system.
“Scott is an innovative senior executive with experience ranging from large commercial to early growth-phase organizations, who has demonstrated strong results from a dynamic blend of operational excellence, commercial leadership, and strategic execution,” said Mark J. Forchette, president and chief executive officer at Delphinus. “He’s passionate about driving disruptive technologies to success, which is in complete alignment with our vision at Delphinus. As we progress with our commercialization activities, we’re focused on expanding our team to meet the needs of our current and future customers, with more than a 30 percent increase in headcount in 2023.”
White is a seasoned medical technology executive, with more than 20 years of experience in commercial, operations, and finance leadership. Prior to joining Delphinus, he was Chief Commercial Officer of Hyperfine, developer of a bedside neurological magnetic resonance imaging (MRI) platform, where he helped lead the development of a new commercial strategy and growth within the company’s strategic global accounts. White previously served as vice president of global sales at Rapid Micro Biosystems, and area vice president at Intuitive Surgical.
“Delphinus is leading the way in the fight against breast cancer with its groundbreaking SoftVue platform. I look forward to working with our great team to bring its benefits to more patients and women’s health centers across the country,” Scott White said.
SoftVue, a 3D whole breast ultrasound tomography system for screening dense breasts, was approved by the U.S. Food & Drug Administration (FDA) in October 2021. When paired with mammography SoftVue has been shown to identify up to 20 percent more cancers while also reducing false positives and decreasing unnecessary call-backs and biopsies in women with dense breasts.
Dense breast tissue (fibrous tissue that can hide cancerous lesions on mammogram) is common, affecting 40 percent of women and making them four times more likely to develop breast cancer. Compounding the increased risk, dense breast tissue like cancer, typically appears white on a mammogram, making it more challenging to detect cancer early.
SoftVue was developed to address the unmet clinical need for early breast cancer detection in individuals with dense breast tissue and provides a new annual screening solution for this population. The system identifies more cancers, with fewer callbacks, using a proprietary TriAD™ (Triple Acoustic Detection) technology that effectively characterizes tissue by recording reflection, speed and direction of sound waves moving through breast tissue, unlike traditional ultrasound which utilizes only reflection. In addition, SoftVue is the only ultrasound-based breast imaging system that was approved by the FDA for same day screening as mammography for this population of women.